Identifying the Intergenic ALK Fusion LOC388942‐ALK as a Driver of Non–Small Cell Lung Cancer
ABSTRACT ALK fusions, such as the classic EML4‐ALK, are known drivers of lung cancer and effective therapeutic targets. However, variant ALK fusions, including intergenic fusions like LOC388942‐ALK (LA), have been detected in increasing numbers of patients, with their roles in tumorigenesis and ALK...
Saved in:
| Main Authors: | Xiaoqian Zhai, Manli Wang, Qi Zhang, Donglin Li, Yanmou Wu, ZuoYu Liang, Jiewei Liu, Weiya Wang, Yu Liu, Guowei Che, Qinghua Zhou, Chong Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70154 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01) -
Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01) -
Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01) -
Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01) -
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
by: Suma Devaraj, et al.